The impact of treatment with palopegteriparatide on bone metabolism in patients with hypoparathyroidism
Osteologie · 2026-10-26
DOI: 10.1055/a-2912-2961 ↗Abstract
Abstract Hypoparathyroidism (HypoPT) is a rare endocrine disorder characterized by insufficient parathyroid hormone (PTH) secretion, resulting in hypocalcemia and disturbed calcium–phosphate homeostasis. Beyond its biochemical abnormalities, HypoPT is associated with a distinct skeletal phenotype of increased bone mineral density (BMD) and markedly reduced bone turnover. This review summarizes the skeletal manifestations of HypoPT and the implications of emerging PTH replacement therapies. Chronic PTH deficiency suppresses bone remodeling, alters microarchitecture, and increases matrix mineralization. Despite elevated BMD, bone quality may be impaired, and fracture risk varies with disease etiology and patient characteristics. Current fracture risk assessment tools are not validated for HypoPT and likely underestimate skeletal risk. Likewise, the role of antiresorptive therapy remains uncertain, as further suppression of bone turnover may aggravate the low-turnover state and reduce skeletal calcium buffering capacity. Conventional treatment corrects hypocalcemia but does not restore physiological PTH action. In contrast, palopegteriparatide transiently increased bone turnover above the normal range, followed by stabilization within the upper normal range. BMD declined from elevated baseline values toward age- and sex-matched norms and remained stable through week 162. Early data suggest that other PTH analogues exert distinct skeletal effects. Future studies should evaluate long-term skeletal outcomes, improve assessment of bone quality, and develop phenotype-guided treatment strategies.
EUVIMED